Posted by Michael Wonder on 26 Oct 2021
Evrysdi is not included in the high-cost protection
22 October 2021 - TLV assesses that the costs of using Evrysdi are too high in relation to the benefit the company has shown.
TLV sees several uncertainties in the economic evaluation. Among other things, it is difficult to assess the size of the treatment effect with continued treatment and the impact on life expectancy.
